RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Structure-activity relationships for 1 ',1 '-dimethylalkyl-Delta(8)-tetrahydrocannabinols
Huffman, J. W., Miller, J. R. A., Liddle, J., Yu, S., Thomas, B. F., Wiley, J. L., & Martin, B. R. (2003). Structure-activity relationships for 1 ',1 '-dimethylalkyl-Delta(8)-tetrahydrocannabinols. Bioorganic and Medicinal Chemistry, 11(7), 1397-1410. https://doi.org/10.1016/S0968-0896(02)00649-1
A series of 1?,1?-dimethylalkyl-?8-tetrahydrocannabinol analogues with C-3 side chains of 2–12 carbon atoms has been synthesized and their in vitro and in vivo pharmacology has been evaluated. The lowest member of the series, 1?,1?-dimethylethyl-?8-THC (8, n=0) has good affinity for the CB1 receptor, but is inactive in vivo. The dimethylpropyl (8, n=1) through dimethyldecyl (8, n=8) all have high affinity for the CB1 receptor and are full agonists in vivo. 1?,1?-Dimethylundecyl-?8-THC (8, n=9) has significant affinity for the receptor (Ki=25.8±5.8 nM), but has reduced potency in vivo. The dodecyl analogue (8, n=10) has little affinity for the CB1 receptor and is inactive in vivo. A quantitative structure–activity relationship study of the side chain region of these compounds is consistent with the concept that for optimum affinity and potency the side chain must be of a length which will permit its terminus to loop back in proximity to the phenolic ring of the cannabinoid.